Comparative Bioavailability Study of UDCA
Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Mar 6, 2015
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI ≥ 19.0 and ≤ 30.0 kg/m2.
- • No clinically significant findings in a 12-lead electrocardiogram (ECG)
- • Be informed of the nature of the study and give written consent prior to any study procedure
- Exclusion Criteria:
- • Known history or presence of any clinically significant medical condition
- • Participated in a clinical trial which involved administration of an investigational medicinal product within 30 days prior to drug administration, or recently participated in a clinical investigation that, in the opinion of the investigator, would jeopardize subject safety or the integrity of the study results
About Daewoong Pharmaceutical Co. Ltd.
Daewoong Pharmaceutical Co., Ltd. is a leading South Korean biopharmaceutical company committed to advancing healthcare through innovative research and development. With a strong focus on the discovery and commercialization of novel therapeutics, Daewoong specializes in a diverse range of therapeutic areas, including gastroenterology, endocrinology, and neurology. The company is dedicated to improving patient outcomes by leveraging cutting-edge technology and scientific expertise, and it actively engages in global clinical trials to bring new treatments to market. Daewoong's commitment to quality and innovation positions it as a key player in the pharmaceutical industry, striving to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials